VSTM:NAS (USA) Also trade in: Germany UK

Verastem Oncology

$ 2.17 -0.06 (-2.69%)
Volume: 1,990,623 Avg Vol (1m): 3,057,577
Market Cap $: 160.31 Mil Enterprise Value $: 31.11 Mil
P/E (TTM): 0.00 P/B: 1.59
Earnings Power Value 0.17
Net Current Asset Value 1.1
Tangible Book 1.13
Projected FCF -4.31
Median P/S Value 5.35
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 2.07
Equity-to-Asset 0.45
N/A
Debt-to-Equity 0.97
Debt-to-EBITDA -1.85
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.03
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 14.61%

Profitability & Growth : 4/10

Current vs industry vs history
Operating Margin % -354.75
N/A
Net Margin % -271.11
N/A
ROE % -79.60
ROA % -45.76
ROC (Joel Greenblatt) % -5830.91
3-Year Total EBITDA Growth Rate -4.50
3-Year EPS w/o NRI Growth Rate 5.20

» VSTM's 30-Y Financials

Financials (Next Earnings Date: 2019-05-03)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:VSTM

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:CALA NAS:CDMO OTCPK:MRMD ROCO:6497 TSX:NEPT NAS:MLNT TPE:1720 HKSE:01035 ROCO:4167 OSTO:BIOA B ROCO:4152 XKRX:217730 NAS:CTIC ROCO:6617 NAS:ARQL NAS:ADMA TSE:2395 TSX:IMV TSX:FRX ASX:BNO
Traded in other countries 2VS.Germany 0LOV.UK
Address 117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is a part of the healthcare sector. It is focused on discovering and developing drugs to aid patients suffering from cancer. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. The company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Ratios

Current vs industry vs history
PB Ratio 1.59
PS Ratio 5.61
EV-to-EBIT -0.47
EV-to-EBITDA -0.48
EV-to-Revenue 1.16
Current Ratio 6.83
Quick Ratio 6.82
Days Inventory 202.63
Days Sales Outstanding 4.18
N/A
Days Payable 22.00

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -23.30

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.93
Price-to-Median-PS-Value 0.41
Earnings Yield (Joel Greenblatt) % -212.77

More Statistics

Revenue (TTM) (Mil) $ 26.72
EPS (TTM) $ -1.38
Beta 2.43
Volatility % 87.83
52-Week Range $ 2.13 - 10.35
Shares Outstanding (Mil) 73.88

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y